eMeasure Title Gout: Anti-Inflammatory Prophylaxis with Urate Lowering Therapy (ULT)
eMeasure Identifier
(Measure Authoring Tool)
eMeasure Version number 0
NQF Number 2526 (Under Consideration) GUID 8c07728d-446f-496c-8953-91b3aa684079
Measurement Period January 1, 20xx through December 31, 20xx
Measure Steward American College of Rheumatology
Measure Developer American College of Rheumatology
Endorsed By None
Description
Percentage of patients aged 18 and older with a diagnosis of gout initiated on urate- lowering therapy (ULT), who are receiving concomitant anti-inflammatory prophylaxis (defined as low dose colchicine, non-steroid anti-inflammatory drug (NSAID) or glucocorticoid)
Copyright
Copyright (C) 2014, American College of Rheumatology

All materials are subject to copyrights owned by the College. The College hereby provides limited permission for the user to reproduce, retransmit or reprint for such user's own personal use (and for such personal use only) part or all of any document as long as the copyright notice and permission notice contained in such document or portion thereof is included in such reproduction, retransmission or reprinting. All other reproduction, retransmission, or reprinting of all or part of any document is expressly prohibited, unless the College has expressly granted its prior written consent to so reproduce, retransmit, or reprint the material. All other rights reserved.
Disclaimer
This performance measure has not been tested for all potential applications. The measure and specifications are provided “as is” and without warranty of any kind.

CPT(R) contained in the Measure specifications is copyright 2004-2013 American Medical Association. LOINC(R) copyright 2004-2013 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2013 International Health Terminology Standards Development Organisation.  ICD-10 copyright 2014 World Health Organization. All Rights Reserved.

Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM].
Measure Scoring Proportion
Measure Type Process
Stratification
None
Risk Adjustment
None
Rate Aggregation
None
Rationale
After initiating urate lowering therapy, there is an increased rate of acute gout flares for several months. For the recent randomized control trials, where prophylaxis was continued for only 8 weeks, 40% of patients flared upon cessation of prophylaxis, whereas if prophylaxis was continued for 6 months, only 5% of patients flared [1].

In a small randomized control trial using colchicine vs. placebo, patients assigned to colchicine had fewer flares at 0-3 and 3-6 months (0.57 and 0 flares) vs. patients assigned to placebo (1.91, 1.05 flares), both differences statistically different [2].

Forty-three subjects were studied. Subjects treated with colchicine experienced fewer total flares (0.52 vs 2.91, p = 0.008), fewer flares from 0 to 3 months (0.57 vs 1.91, p = 0.022), fewer flares 3-6 months (0 vs 1.05, p = 0.033), less severe flares as reported on 
VAS (3.64 vs 5.08, p = 0.018), and fewer recurrent gout flares (p = 0.001). Colchicine was well tolerated.
Clinical Recommendation Statement
Pharmacologic anti-inflammatory prophylaxis is recommended for all gout patients when pharmacologic urate lowering is initiated, and should be 
continued if there is any clinical evidence of continuing gout disease activity and/or the serum urate target has not yet been achieved.

Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or oral colchicine are appropriate first-line options for treatment of acute gout, and 
certain combinations can be employed for severe or refractory attacks.

Khanna, Dinesh, et. al. 2012 American College of Rheumatology
Guidelines for Management of Gout. Part 2: Therapy and Anti-inflammatory Prophylaxis of Acute Gouty Arthritis. Arthritis Care & Research 2012; 64: 1447-61.
Improvement Notation
Higher score indicates better quality
Reference
[1] Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate lowering therapy: analysis of data from three phase III trials. Clin Ther 2010;32:2386–97.
Reference
[2] Borstad GC, Bryant LR, Abel MP, Scroogie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429–32.
Definition
Prescribed includes prescription for anti-inflammatory prophylaxis ordered at the most recent visit in the measurement period OR patient actively taking anti-inflammatory prophylaxis at the time of the most recent visit as documented in the current medication list.
Guidance
For this measure, a patient qualifies for a ‘Medical Reason’ denominator exception only when the patient has a documented contraindication, allergy or intolerance to each of the three anti-inflammatory prophylaxis (eg, low-dose colchicine, NSAID, and glucocorticoid) medications included in the numerator; if a patient has a documented contraindication, allergy or intolerance to one or two of the drug classes, it would be expected that a medication from the remaining class(es) would be prescribed.
Transmission Format
TBD
Initial Patient Population
Patients aged 18 and older with an established gout diagnosis initiating urate lowering (ULT) therapy
Denominator
Equals Initial Patient Population
Denominator Exclusions
None
Numerator
Patients prescribed anti-inflammatory prophylaxis (including low-dose colchicine, non-steroidal anti-inflammatory (NSAID) or glucocorticoid)
Numerator Exclusions
Not Applicable
Denominator Exceptions
Documentation of medical reason(s) for not prescribing any of the options for anti-inflammatory prophylaxis (eg, patients with eGFR<30 mL/min or Stage 3 or greater Chronic Kidney Disease AND poorly controlled diabetes (diagnosis of diabetes and HbA1c > 9), other medical reason)
Measure Population
Not Applicable
Measure Observations
Not Applicable
Supplemental Data Elements
For every patient evaluated by this measure also identify payer, race, ethnicity and sex.

Table of Contents


Population criteria

Data criteria (QDM Data Elements)

Reporting Stratification

Supplemental Data Elements




Measure Set
American College of Rheumatology - Gout Measurement Set